Clinicopathologic Characteristics According to Recurrence
| Characteristic | Overall | Recurrence | Nonrecurrence | P |
| Patients (n) | 110 | 30 | 80 | |
| Sex (n) | 89 M:21 F | 24 M:6 F | 6 M:15 F | 0.882 |
| Age, mean (y) | 54 ± 9 (range, 22–72) | 53 ± 12 (range, 22–72) | 55 ± 7 (range, 33–71) | 0.301 |
| Follow-up time, mean (mo) | 45.6 ± 18.0 (range, 7.4–83.1) | 22.9 ± 35.0 (range, 7.4–64.2) | 48.6 ± 55.0 (range, 27.5–83.1) | <0.001 |
| Viral status | ||||
| HBV | 86 (78%) | 22 (73%) | 64 (80%) | |
| HCV | 16 (15%) | 4 (13%) | 12 (15%) | |
| Neither HBV nor HCV | 8 (7%) | 4 (13%) | 4 (5%) | |
| Pretransplantation α-fetoprotein, median (ng/mL) | 22.2 (range, 1.0–1,708,000) | 141.9 (range, 1.0–1,708,000) | 15.2 (range, 1.5–1597) | 0.215 |
| Donor (n) | 0.706 | |||
| LDLT | 93 (85%) | 26 (87%) | 67 (84%) | |
| DDLT | 17 (15%) | 4 (13%) | 13 (16%) | |
| Tumor size, mean (cm) | 3.8 ± 3.6 | 6.6 ± 5.5 | 2.7 ± 1.6 | 0.001 |
| Tumor number (n) | 0.011 | |||
| Single | 37 (34%) | 4 (13%) | 33 (41%) | |
| Multiple | 73 (66%) | 26 (87%) | 47 (59%) | |
| Milan criteria (n) | 0.003 | |||
| Within | 55 (50%) | 8 (27%) | 47 (59%) | |
| Beyond | 55 (50%) | 22 (73%) | 33 (41%) | |
| Tumor necrosis, mean (%) | 37.5 ± 41.8 | 41.6 ± 40.1 | 36.0 ± 42.6 | 0.535 |
| Tumor grade (n) | 0.003 | |||
| 1/2 | 45 (41%) | 5 (17%) | 40 (50%) | |
| 3/4 | 65 (59%) | 25 (83%) | 40 (50%) | |
| Vascular invasion (n) | <0.001 | |||
| No | 84 (76%) | 14 (47%) | 70 (88%) | |
| Yes | 26 (24%) | 16 (53%) | 10 (13%) | |
| T-stage (n) | 0.002 | |||
| T1/T2 | 45 (41%) | 5 (17%) | 40 (50%) | |
| T3/T4 | 65 (59%) | 25 (63%) | 40 (50%) |
HBV = hepatitis B virus; HCV = hepatitis C virus; LDLT = living donor liver transplantation; DDLT = deceased donor liver transplantation.